ADVERTISEMENT
Treatment Produces Rapid, Sustained Response in Multiple Type 2 Inflammatory Diseases
Treatment with dupilumab yielded clinically meaningful responses in patients with type 2 inflammatory diseases including atopic dermatitis (AD), asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP). Findings were published in the Journal of Allergy and Clinical Immunology: In Practice.
“Type 2 inflammatory diseases often coexist in patients,” researchers said. “Dupilumab targets type 2 inflammation and has demonstrated treatment benefits…with an acceptable safety profile.”
The post hoc analysis was conducted using data from five phase 3 studies. Patients had moderate-to-severe AD, moderate-to-severe asthma, or severe CRSwNP and were treated with either placebo or dupilumab at a dosage of 200/300 mg.
After 2 weeks of receiving dupilumab, there was a clinically meaningful benefit in 67.8% of patients with AD, compared to 36.5% of those receiving placebo (P < .001). Researchers defined this benefit as an Eczema Area and Severity Index score improvement ≥50%; a Peak Pruritis Numerical Rating Scale improvement ≥3 points; or a Dermatology Life Quality Index improvement ≥4 points.
Regarding asthma, prebronchodilator FEV1 improved by ≥100 mL in 61.6% of patients treated with dupilumab vs 39.9% in the placebo group (P < .001). Findings also showed 48.8% of patients saw improvements ≥200 mL in the dupilumab arm compared to 26.3% of those receiving placebo (P < .001).
Among those with CRSwNP, 33.2% of patients regained their smell after being treated with dupilumab vs 5.6% of patients treated with placebo (P < .001).
Researchers concluded patients with AD, asthma, or CRSwNP achieved rapid, clinically meaningful responses after their first dose of dupilumab, and benefits were sustained or improved over time.
Reference:
Canonica GW, Bourdin A, Peters AT, et al. Dupilumab demonstrates rapid onset of response across three type 2 inflammatory diseases. J Allergy Clin Immunol Pract. 2022;10(6):1515-1526. doi:10.1016/j.jaip.2022.02.026
